PuSH - Publication Server of Helmholtz Zentrum München: The <em>CTRB1/2</em> locus affects diabetes susceptibility and treatment via the incretin pathway.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

't Hart, L.M.* ; Fritsche, A. ; Nijpels, G.* ; van Leeuwen, N.* ; Donnelly, L.A.* ; Dekker, J.M.* ; Alssema, M.* ; Fadista, J.* ; Carlotti, F.* ; Gjesing, A.P.* ; Palmer, C.N.* ; van Haeften, T.W.* ; Herzberg-Schäfer, S.A.* ; Simonis-Bik, A.M.C.* ; Houwing-Duistermaat, J.J.* ; Helmer, Q.* ; Deelen, J.* ; Guigas, B.* ; Hansen, T.* ; Machicao, F.* ; Willemsen, G.* ; Heine, R.J.* ; Kramer, M.H.* ; Holst, J.J.* ; de Koning, E.J.* ; Häring, H.-U. ; Pedersen, O.* ; Groop, L.* ; de Geus, E.J.* ; Slagboom, P.E.* ; Boomsma, D.I.* ; Eekhoff, E.M.* ; Pearson, E.R.* ; Diamant, M.*

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.

Diabetes 62, 3275-3281 (2013)

Publ. Version/Full Text

DOI

PMC

	Closed

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances β-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P ≤ 8.8 × 10(-7)). rs7202877 near CTRB1/2, a known diabetes risk locus, also associated with an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but there was no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527). Furthermore, in pancreatic tissue, we show that rs7202877 acts as expression quantitative trait locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most abundant digestive enzymes in the gut where it cleaves food proteins into smaller peptide fragments. Our data identify chymotrypsin in the regulation of the incretin pathway, development of diabetes, and response to DPP-4 inhibitor treatment.

Impact Factor

Scopus SNIP

Scopus
Cited By

Altmetric

0.000

2.093